E
3.74
0.12 (3.31%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | enGene Holdings Inc. | 看涨 | 看跌 |
AIStockmoo 评分
2.1
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.13 |
|
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 13.63% |
| 机构持股比例 | 77.57% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (HC Wainwright & Co., 568.45%) | 购买 |
| 中 | 21.50 (474.87%) | |
| 低 | 18.00 (Morgan Stanley, 381.28%) | 购买 |
| 平均值 | 21.50 (474.87%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 6.06 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 25.00 (568.45%) | 购买 | 6.06 |
| 08 Sep 2025 | 25.00 (568.45%) | 购买 | 5.43 | |
| Morgan Stanley | 12 Sep 2025 | 18.00 (381.28%) | 购买 | 6.06 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合